RT Journal Article SR Electronic T1 Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis JF BMJ Open Gastroenterology FD BMJ Publishing Group Ltd SP e000127 DO 10.1136/bmjgast-2016-000127 VO 4 IS 1 A1 Johannes Bethge A1 Silvia Meffert A1 Mark Ellrichmann A1 Claudio Conrad A1 Susanna Nikolaus A1 Stefan Schreiber YR 2017 UL http://bmjopengastro.bmj.com//content/4/1/e000127.abstract AB Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA.